<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1898">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136456</url>
  </required_header>
  <id_info>
    <org_study_id>RSB20926</org_study_id>
    <nct_id>NCT05136456</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in&#xD;
      patients with primary membranous nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase II study to evaluate the efficacy and safety of SHR1459 tablets in&#xD;
      patients with primary membranous nephropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving complete or partial remission at week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Proportion of subjects achieving complete or partial remission at week 24</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>SHR1459 Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR1459 SHR1459 oral 24weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR1459 High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR0302 SHR1459 oral 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Placebo oral 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1459 Low Dose</intervention_name>
    <description>SHR1459 oral tablets taken once daily (QD) for 24weeks</description>
    <arm_group_label>SHR1459 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1459 High Dose</intervention_name>
    <description>SHR1459 oral tablets taken once daily (QD) for 24 weeks</description>
    <arm_group_label>SHR1459 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral tablets taken once daily (QD) for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Diagnosis of primary membranous nephropathy based on renal biopsy within 6 months&#xD;
             before screening 2. Have not received any previous immunosuppressive therapy for&#xD;
             primary membranous nephropathy 3. PLA2R-Ab positive with titer between 20RU/mL to&#xD;
             150RU/mL (include two ends) at screening 4. 24-hour urinary protein at mile to&#xD;
             moderate risk at screening 5. Have eGFR â‰¥ 60 mL/min/1.73 m2 (based on CKD-EPI formula)&#xD;
             at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Any clue for coexist of secondary membranous nephropathy from medical records,&#xD;
             laboratory tests or kidney biopsy 2. Existence of clinically significant infection&#xD;
             within 1 month before screening, 3. Severe or not well controlled other complications&#xD;
             4. Abnormal in white blood cell count, neutrophil count, lymphocyte count or platelet&#xD;
             count at screening, which were considered unfit for participating judged by&#xD;
             investigators 5. ALT &gt; 2 times ULN and/or AST &gt; 2 times ULN and/or bilirubin &gt;2 times&#xD;
             ULN at screening 6. Subject has evidence of active, latent, or inadequately treated&#xD;
             infection with Mycobacterium tuberculosis 7. Positive of hepatitis B surface antigen,&#xD;
             hepatitis C antibody, HIV antibody or syphilis antibody at screening;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kai Yuan</last_name>
    <phone>86 13401206014</phone>
    <email>kai.yuan@reistonebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imran Ghiasuddin</last_name>
    <email>co.us@reistonebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonggui Wu</last_name>
    </contact>
    <investigator>
      <last_name>Yonggui Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Gao</last_name>
    </contact>
    <investigator>
      <last_name>Qing Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changying Ni</last_name>
    </contact>
    <investigator>
      <last_name>Changying Ni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital of Jiangsu province</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhua Liu</last_name>
    </contact>
    <investigator>
      <last_name>Changhua Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang He</last_name>
    </contact>
    <investigator>
      <last_name>Qiang He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaosheng Chen</last_name>
    </contact>
    <investigator>
      <last_name>Chaosheng Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Ni</last_name>
    </contact>
    <investigator>
      <last_name>Zhaohui Ni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Wen Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yu</last_name>
    </contact>
    <investigator>
      <last_name>Chen Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gengru Jiang</last_name>
    </contact>
    <investigator>
      <last_name>Gengru Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

